Cresco Labs Inc. (CRLBF)
(Delayed Data from OTC)
$2.25 USD
+0.10 (4.58%)
Updated May 2, 2024 11:34 AM ET
2-Buy of 5 2
B Value B Growth F Momentum A VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
CRLBF 2.25 +0.10(4.58%)
Will CRLBF be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for CRLBF based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CRLBF
Investors Heavily Search Cresco Labs Inc. (CRLBF): Here is What You Need to Know
Cresco Labs Inc. (CRLBF) Flat As Market Sinks: What You Should Know
CRLBF: What are Zacks experts saying now?
Zacks Private Portfolio Services
Brokers Suggest Investing in Cresco Labs Inc. (CRLBF): Read This Before Placing a Bet
Is Cresco Labs Inc. (CRLBF) Stock Outpacing Its Medical Peers This Year?
Cresco Labs Inc. (CRLBF) Stock Dips While Market Gains: Key Facts
Other News for CRLBF
Teamsters Unionize Cannabis Workers At Another Cresco Labs' Dispensary In Illinois, 'It Feels Good'
DEA Moves To Reschedule Weed, Cannabis Stocks Go For Wild Ride, Pummel Short Sellers With $210M In Losses
Schumer eyes more cannabis reforms after ‘historic’ marijuana rescheduling decision
Pot stocks rally snuffed day after DEA marijuana rescheduling development
OMB review of cannabis rescheduling could put measure at risk